Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a note issued to investors on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

NERV stock opened at $2.21 on Thursday. Minerva Neurosciences has a 1-year low of $2.06 and a 1-year high of $13.49. The business has a fifty day moving average price of $2.38 and a 200-day moving average price of $2.75. The stock has a market capitalization of $15.45 million, a P/E ratio of -5.02 and a beta of 0.11.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.